PDUFA VI "Breakthrough" Fee Unlikely; US FDA Wants Fewer Obligations, Not New Metrics
This article was originally published in SRA
Officials of the US Food and Drug Administration negotiating the Prescription Drug User Fee Act VI (PDUFA VI) agreement say they would be hesitant to ask for user fees from the pharmaceutical industry specifically to fund the "breakthrough designation program" - even if the fees would help offset the agency's unexpectedly heavy workload and reduce the number of unqualified requests for the designation1,2.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.